Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2017-08-27 Notice of Dividend Amou…
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Dividend/Distribution - CYC 3 pages 26.4KB
Notice of Dividend Amount Classification · 100% confidence The document is a notification of dividend/distribution for Cyclopharm Limited, detailing the dividend amount, ex-date, record date, and payment date. It does not contain financial statements or analysis but is an announcement of dividend payment details. The document length is 4124 characters, which is relatively short and consistent with a dividend announcement rather than a full report. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2017-08-27 English
Cyclopharm Limited 1H2017 Results Investor Presentation 24 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is titled '1H2017 Results Investor Presentation' and contains detailed financial data for the half year ended 30 June 2017, including sales revenue, gross margin, net loss, EBITDA, balance sheet figures, cash flow, and strategic priorities. It also includes operational highlights, market opportunity, clinical trial information, and outlook. The content is comprehensive and typical of an investor presentation focusing on financials, strategy, and market position. It is not a full annual or interim report, nor is it a regulatory filing or announcement. The presence of slides, charts, and strategic commentary further supports classification as an Investor Presentation.
2017-08-27 English
Nuclear imaging trial aiming to clear up airway diagnosis 2 pages 125.8KB
Regulatory Filings Classification · 90% confidence The document is a press release or announcement about a new nuclear imaging trial for respiratory diseases, describing the study's purpose, collaborators, and expected outcomes. It does not contain any financial data, regulatory filing references, or corporate governance information. It is not a report, financial statement, or regulatory filing. The content is informational about a research study and collaboration, typical of a general regulatory announcement or news update. Given the lack of fit with other categories, the best classification is Regulatory Filings (RNS) as a fallback category for miscellaneous announcements.
2017-08-17 English
CYC CEO To Present at Bioshares 2017 Biotech Conference 39 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is a detailed investor presentation from Cyclopharm Limited, dated 22 July 2017, presented at the Bioshares 2017 Biotech Summit. It contains extensive information about the company's business model, product overview, market strategy, clinical trials, sales data, and growth opportunities. The content is focused on financials, strategy, market position, and product development rather than regulatory filings, audit reports, or formal financial statements. There is no indication that this is an official annual or interim report, audit report, or earnings release. The document is too long and detailed to be a simple announcement or regulatory filing. It fits the description of an Investor Presentation (IP) which typically includes comprehensive company and financial information aimed at investors.
2017-07-20 English
Change in substantial holding - Barings Acceptance Limited 3 pages 1.1MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001. It details changes in voting power and relevant interests of a substantial shareholder in Cyclopharm Limited. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure about shareholding changes.
2017-07-05 English
Change in substantial holding - Chemical Trustee Limited 3 pages 1.1MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, specifically a Notice of change of interests of a substantial holder. It details changes in voting power, relevant interests, and shareholdings of a substantial holder in Cyclopharm Limited. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure about shareholding changes.
2017-07-05 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.